Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote. The Oncologic Drugs ...
The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by rejecting AstraZeneca’s PT010, a close competitor. AZ has confirmed that ...
A digital advertising board is due to replace several existing signs at a service station in Castleton. The new digital hoarding will be put up at Castleton Service Station, Newport Road, Cardiff, ...
Goodbye for 2025 - here are some great reads for the festive period It's been a year in which market swings and political zigzagging on both sides of the Atlantic had tangible impacts on your finances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback